Telisotuzumab vedotin
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Telisotuzumab vedotin |
| Trade Name | Emrelis |
| Synonyms | ABBV-399|Teliso-V|telisotuzumab vedotin-tllv |
| Drug Descriptions |
Emrelis (telisotuzumab vedotin) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET-expressing tumor cells, resulting in cell death (PMID: 27573171, PMID: 32127466). Emrelis (telisotuzumab vedotin) is FDA-approved for use in patients with non-squamous non-small cell lung cancer with high Met overexpression (FDA.gov). |
| DrugClasses | MET Antibody 36 |
| CAS Registry Number | 1781223-80-0 |
| NCIT ID | C118571 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
CKB BOOST